(MedPage Today) — The FDA has approved a new sublingual tablet formulation of the opioid addiction drug buprenorphine-naloxone (Zubsolv), drugmaker Orexo U.S. announced. (Source: MedPage Today Psychiatry)
FDA OKs New Formula for Addiction Drug
Previous post: Buprenorphine therapy: an increasing challenge in oral and maxillofacial surgery
Next post: First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland
